论文部分内容阅读
目的 观察思密达治疗肠易激综合征 (IBS)的疗效和安全性。方法 采用双盲对照实验 ,68例患者随机分为 2组。疗程 60天 ,治疗组口服思密达 3袋 /天 ,对照组口服安慰剂 ,使用方法相同。前 30天治疗有效者进行下一阶段治疗 (30天 )。疗效评价标准如下 :大便次数 ;患者主观症状 ,包括腹痛、腹胀 ,其严重程度以计分评估。结果 同安慰剂相比 ,思密达治疗IBS的疗效明显优于安慰剂 (P <0 .0 1) ;其在缓解患者腹痛、腹胀症状方面也显示出很好的疗效 (P <0 .0 1)。结论 思密达是一有效 ,安全的治疗IBS药物
Objective To observe the efficacy and safety of simitam in the treatment of irritable bowel syndrome (IBS). Methods Double-blind control experiment, 68 patients were randomly divided into two groups. Course of 60 days, the treatment group oral Smecta up to 3 bags / day, the control group oral placebo, the same method of use. The first 30 days of treatment effective for the next phase of treatment (30 days). Efficacy evaluation criteria are as follows: stool frequency; subjective symptoms of patients, including abdominal pain, abdominal distension, the severity of the scoring evaluation. Results Compared with placebo, Smectite was superior to placebo in the treatment of IBS (P <0.01). It also showed good efficacy in relieving abdominal pain and bloating symptoms (P <0. 0) 1). Conclusion Smectite is an effective and safe treatment of IBS